Swiss National Bank lifted its holdings in Diplomat Pharmacy Inc (NYSE:DPLO) by 20.3% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 110,800 shares of the company’s stock after buying an additional 18,700 shares during the period. Swiss National Bank owned approximately 0.15% of Diplomat Pharmacy worth $675,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. KBC Group NV bought a new position in shares of Diplomat Pharmacy in the second quarter worth $46,000. BNP Paribas Arbitrage SA increased its stake in Diplomat Pharmacy by 446.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 13,104 shares of the company’s stock valued at $76,000 after purchasing an additional 10,708 shares in the last quarter. Acorn Wealth Advisors LLC acquired a new position in Diplomat Pharmacy during the 1st quarter valued at approximately $82,000. Aperio Group LLC increased its stake in shares of Diplomat Pharmacy by 127.0% in the second quarter. Aperio Group LLC now owns 28,304 shares of the company’s stock worth $172,000 after acquiring an additional 15,834 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Diplomat Pharmacy in the first quarter worth $118,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Shares of NYSE:DPLO traded down $0.27 during midday trading on Friday, hitting $5.72. The company’s stock had a trading volume of 14,734 shares, compared to its average volume of 740,879. The business’s 50 day simple moving average is $5.60 and its 200 day simple moving average is $5.55. The company has a debt-to-equity ratio of 1.53, a quick ratio of 0.66 and a current ratio of 0.99. The company has a market cap of $502.00 million, a P/E ratio of 28.80 and a beta of 1.01. Diplomat Pharmacy Inc has a 12-month low of $4.17 and a 12-month high of $21.48.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.01). The business had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.23 billion. Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. The business’s quarterly revenue was down 9.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.05) earnings per share. On average, sell-side analysts predict that Diplomat Pharmacy Inc will post -0.78 earnings per share for the current fiscal year.

Several research firms recently commented on DPLO. Zacks Investment Research lowered shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Wednesday, August 14th. ValuEngine upgraded shares of Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Barclays set a $7.00 price target on shares of Diplomat Pharmacy and gave the company a “buy” rating in a research report on Friday, August 9th. Wells Fargo & Co raised their price target on shares of Diplomat Pharmacy from $5.00 to $5.50 and gave the company a “market perform” rating in a research report on Tuesday, August 13th. Finally, Deutsche Bank assumed coverage on shares of Diplomat Pharmacy in a report on Thursday. They set a “sell” rating and a $4.00 price objective on the stock. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $9.43.

Diplomat Pharmacy Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Story: Momentum Investing

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.